Table 2.

Current clinical trials investigating the use of immune checkpoint inhibitor with targeted agents in metastatic RCC.

NCT number	Phase	Histology	Intervention	Control	Primary Endpoint	Treatment Setting	Status
NCT03937219 (COSMIC 313)	III	Clear cell	Nivolumab & ipilimumab + cabozantinib	Nivolumab & ipilimumab only	PFS	First line	Recruiting
NCT03729245	III	Clear cell	Bempegaldesleukin & nivolumab	Sunitinib or cabozantinib	ORR, OS	First line	Recruiting
NCT03873402	III	Clear cell	Nivolumab & ipilimumab	Nivolumab alone	ORR, PFS	First line	Active, not recruiting
NCT04394975	III	Clear cell	Toripalimab & axitinib	Sunitinib	PFS	First line	Recruiting
NCT03260894	III	Clear cell	Pembrolizumab & epacadostat	Sunitinib or pazopanib	ORR	First line	Active, not recruiting
NCT03793166 (PDIGREE)	III	Clear cell	Ipilimumab & nivolumab followed by maintenance nivolumab & cabozantinib	Ipilimumab & nivolumab followed by maintenance nivolumab only	OS	First line	Recruiting
NCT03289962	I	Multiple cancers including ccRCC	Autogene cevumeran & atezolizumab	NA	DLT RP2D Adverse events	Subsequent line	Recruiting
NCT02964013	I	Multiple cancers including ccRCC	Vibostolimab (Anti-TIGIT antibody) & pembrolizumab	NA	DLT Adverse events	Subsequent line	Recruiting
NCT02655822	I	ccRCC	Ciforadenant (A2AR inhibitor) & atezolizumab	NA	DLT ORR Adverse events	Subsequent line	Recruiting
NCT02754141	I	Multiple cancers including ccRCC	BMS-986179 (CD73 inhibitor) & nivolumab	NA	Adverse events	Subsequent line	Recruiting

OS, overall survival; PFS, Progression-free survival; ORR, Objective response rate; DLT, Dose-Limiting Toxicites; RP2D, Recommended Phase 2 Dose.